Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma

Plain-language summary

This study examined several genetic and cytogenetic diagnostic methods in patients with aggressive non-Hodgkin's lymphoma. Patients aged 18 and over with histologically confirmed aggressive non-Hodgkin's lymphoma enrolled in certain CALGB protocols could take part. It was carried out as a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Alliance for Clinical Trials in Oncology

Intervention

comparative genomic hybridization, cytogenetic analysis, fluorescence in situ hybridization, gene rearrangement analysis

Start date

6/1/1999

Estimated completion

5/1/2005

Countries

United States

Related genes

Locations

• Anniston, United States
• La Jolla, United States
• San Diego, United States
• San Diego, United States
• San Francisco, United States
• San Francisco, United States
• Newark, United States
• Washington D.C., United States
• Washington D.C., United States
• Washington D.C., United States
• Fort Lauderdale, United States
• Hollywood, United States
• Miami Beach, United States
• Chicago, United States
• Chicago, United States
• Chicago, United States
• Peoria, United States
• River Forest, United States
• Fort Wayne, United States
• Iowa City, United States
• Louisville, United States
• Baltimore, United States
• Boston, United States
• Worcester, United States
• Saint Joseph, United States
• Minneapolis, United States
• Minneapolis, United States
• Columbia, United States
• Columbia, United States
• Kansas City, United States
• St Louis, United States
• Omaha, United States
• Las Vegas, United States
• Las Vegas, United States
• Hooksett, United States
• Lebanon, United States
• Camden, United States
• Buffalo, United States
• East Syracuse, United States
• Elmhurst, United States

+29

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

DISEASE CHARACTERISTICS:

* Histologically proven aggressive non-Hodgkin's lymphoma and registered to front-line CALGB protocols (e.g, CLB-59903, 59909, 10002, and 50103)

  * Diffuse small cleaved cell lymphoma
  * Diffuse mixed small and large cell lymphoma
  * Diffuse large cell lymphoma
  * Diffuse large cell immunoblastic lymphoma
  * Small noncleaved cell lymphoma
  * Mantle cell lymphoma OR
* Previously entered on similar curative CALGB protocols (CLB-8852, CLB-8854, and CLB-9351) with blocks or unstained slides of initial diagnosis available

PATIENT CHARACTERISTICS:

Age:

* 18 years and older